Kentucky is currently home to 1059 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/09/2025
Locations: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/08/2025
Locations: Altimmune Clinical Study Site, Louisville, Kentucky
Conditions: Alcohol Liver Disease
Register for Updates
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Site 52, Louisville, Kentucky
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
Mirikizumab Real World Protocol
NCT06696014
Recruiting
The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Louisville, Clinical Trials Unit, Louisville, Kentucky
Conditions: Ulcerative Colitis
Register for Updates
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Norton Pulmonary Specialists, Louisville, Kentucky
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
NCT06324201
Recruiting
Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment to this sub-study per inclusion and exclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Norton Heart and Vascular Institute, Louisville, Kentucky
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Perf-Fix Study for Chronic Tympanic Membrane Repair
NCT06083181
Recruiting
The purpose of the study is to assess the effectiveness of Perf-Fix as a gel patch to aid in the natural healing process to close chronic, \>25% tympanic membrane perforation.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/08/2025
Locations: Advanced ENT & Allergy, Louisville, Kentucky
Conditions: Tympanic Membrane Perforation
Register for Updates
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Advanced Solid Malignancies
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Baptist Health, Lexington, Kentucky
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189
Recruiting
This first-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, or an anti-huma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Kentucky Chandler Medical Center, Lexington, Kentucky
Conditions: Non-Small Cell Lung Cancer
Register for Updates
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Neuroscience Associates of Northern Kentucky, Crestview Hills, Kentucky
Conditions: Pain
Register for Updates
Improving Behavioral Health for Caregivers and Children After Pediatric Injury
NCT06856057
Recruiting
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This propos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Kentucky Children's Hospital, Lexington, Kentucky
Conditions: Quality of Life, PTSD, Depression Not Otherwise Specified, Child Externalizing Behavior
Register for Updates